Since 2022, securities companies have intensively investigated listed companies, and many securities companies have focused on pharmaceutical stocks. The traditional Chinese medicine sector in the pharmaceutical field has performed strongly since November 2021, and in the research, traditional Chinese medicine companies are the focus of various securities companies.
brokerage research busy
According to the data of China stock market news choice, at present, many securities companies have investigated more than 10 or even dozens of listed companies, of which the frequency of pharmaceutical stocks is the highest, and some securities companies have investigated multiple pharmaceutical stocks in one day.
For example, China Merchants Securities Co.Ltd(600999) surveyed four pharmaceutical companies on January 5, namely Huadong Medicine Co.Ltd(000963) , Teyi Pharmaceutical Group Co.Ltd(002728) , Guiyang Xintian Pharmaceutical Co.Ltd(002873) and Zhejiangtailin Bioengineering Co.Ltd(300813) ; China Industrial Securities Co.Ltd(601377) investigated three pharmaceutical companies on January 5, namely Huadong Medicine Co.Ltd(000963) , Aier Eye Hospital Group Co.Ltd(300015) and Cofoe Medical Technology Co.Ltd(301087) ; Citic Securities Company Limited(600030) investigated three pharmaceutical companies on January 12, namely Apeloa Pharmaceutical Co.Ltd(000739) , Boya Bio-Pharmaceutical Group Co.Ltd(300294) and Inkon Life Technology Co.Ltd(300143) .
Not only are securities companies paying attention to and investigating pharmaceutical stocks, but other institutions also pay attention to pharmaceutical stocks. Since 2022, 16 listed companies have received more than 100 research institutions, including 5 pharmaceutical companies. For example, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) has received 427, Huadong Medicine Co.Ltd(000963) 379, Apeloa Pharmaceutical Co.Ltd(000739) 181, Andon Health Co.Ltd(002432) 161, Teyi Pharmaceutical Group Co.Ltd(002728) 101. Both Andon Health Co.Ltd(002432) and Teyi Pharmaceutical Group Co.Ltd(002728) are recent hot stocks. Teyi Pharmaceutical Group Co.Ltd(002728) has increased by more than 40% since November last year, while Andon Health Co.Ltd(002432) has increased by more than 1000% since November last year.
optimistic about the traditional Chinese medicine sector
As the most popular sector in the recent pharmaceutical field, traditional Chinese medicine has been unanimously favored by securities companies.
For the investment opportunities in the pharmaceutical sector in the first half of 2022, Caitong Securities Co.Ltd(601108) said that they are mainly in two aspects: first, deep value, which can be understood as low valuation, low stock price position and good chip structure. Industries with low valuation include traditional Chinese medicine, blood products, pharmacies, etc; Second, consumption growth. Some enterprises transfer their product channels to pharmacies and the Internet. The vast majority of successful transformation are traditional Chinese medicine consumer goods and consumer medical device enterprises.
Southwest Securities Co.Ltd(600369) said that it continued to be optimistic about the traditional Chinese medicine sector in January. From the perspective of valuation, the traditional Chinese medicine sector has experienced many years of correction since 2015, and the current price earnings ratio (TTM) is 34.2 times. At the same time, from a fundamental point of view, there are three opportunities: first, the price of upstream traditional Chinese medicine has increased, and the price of downstream products has increased one after another; Second, the inventory clearance of downstream channels is coming to an end, and the inventory turnover is accelerated, which is expected to usher in the replenishment cycle; Third, the mixed reform of state-owned enterprises will release dividends, and equity incentives will be implemented one after another, greatly releasing the enthusiasm of employees, which is expected to be realized to the performance end in the future.
